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The phosphorylation of signalling proteins on tyro- 
sine is essential for cellular regulation of growth and 
differentiation. Many oncogenes and their cellular 
homologues are protein tyrosine kinases (PTKs), and 
excessive tyrosine phosphorylation has been corre- 
lated with cellular transformation ~,2. The level of 
tyrosine phosphorylation in the cell is also modu- 
lated by specific protein tyrosine phosphatases 
(PTPs). In many cases we know that the activity of 
individual PTPs responds to signals of growth and 
development but we are only beginning to under- 
stand how these enzymes initiate or modulate cellu- 
lar responses to these signals. 
The PTPs are a family of enzymes united by a com- 
mon catalytic core domain but containing diverse 
attached sequences devoted to the regulation of 
activity, substrata recognition, or localization to sub- 
cellular comparunents 3.s (Fig. 1). The catalytic core 
is -250 amino acids long, and contains -21 invariant 
residues, many of which have been shown to be 
necessary for phosphatase activity 6. Within the 
core domain is the active-site signature motif 
[I/V]HCxAGxxR[SfI']G (In the one-letter amino acid 
code where x can be any amino acid). The cysteine 
within this sequence ts required for catalytic activity, 
and is involved in the formation of a phosphoryl- 
enzyme lnterm~late 6. Sequences outside the catalytic 
core of the PTP include Src homology region 2 (SH2) 
domains (which modulate phosphatase interactions 
with other proteins) extraceUular ligand-blndtng 
domains, and signal sequences that direct PTPs to the 
cytoplasmic membrane, the nucleus, and other com- 
partments. Although all PTPs recognize phospho- 
tyroslne<ontalnlng proteins as substrates, a subset, the 
dual-specific phosphatases, recognizes proteins phos- 
phorylated on both tyroslne and serine/threonine. 
The family affiliations and proposed functions of 
VI'Ps discussed in this article are outlined in "gable 1. 
The Yenlnla plrp and Rs role in pathogenicity 
Three species of the bacterial genus Yerstnta are 
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Given the importance of tyrosine phosphorylation of proteins in 
signalling pathways, it is perhaps not surprising that protein 
O,rosine phosphatases (PTPs) a~e involved in the patho, genesis of 
certain human diseases. A PTP produced by the Yersinia bacteria 
(which can cause bubonic plague, septicemia and enteric diseases) 
is thought to be used as a 'weapon' against host cell functions. In 
addition, dysfunction of cells" endogenous PTPs may contribute to 
defective immune function, to cancer and to diabetes. 
cause of bubonic plague, while Y. enterocolitica and Y. 
pseudotuberculosis cause a variety of enteric illnesses 
and septicemia. Yersiniapestis enters the dermal lyre- 
phatics through the bite of an injected flea. The 
enteropathogenic Yersiniae traverse the epithelial cell 
layer in the small intestine and colonize the Peyer's 
patch, a specialized lymphoid follicle. The bacteria 
encounter and evade destruction by lymphocytes 
and macrophages and replicate extracellularly in the 
retlculoendotheltal system. 
The enteropathogenic Yerslniae can be internalized 
Into epithelial cells by three known routes, one of 
which, lnvasln-mediated uptake, is the best under- 
stood 7,~. The chromosomal inv gene encodes the pro- 
tein invasin, which mediates binding of bacteria to 
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T A B L E  1 - FUNCTION OF PTPs 
PTP Family Function 
Yersinio YopH PTP 
Vaccinia VH1 Dual-specific PTP 
HCP SH2-domain PTP 
csw SH2-domain PTP 
SH-PTP2/Syp St42 domain PTP 
Dephosphorylation of unknown substrates in host phagocytes; essential for 
bacterial pathogenicity. 
Dephosphorylation of unknown substrates in mammalian cells; expressed late 
in viral infection. 
Dephosphorylation of unknown substrates in cells of haematopoietic origin; 
mutation leads to abnormal development of these cells in mice, and possibly 
immunological dysfunction in humans. 
Dephosphorylation of unknown substrates during Drosophila development; 
transduces signals from the torso receptor; mutation leads to morphological 
abrlorrnalities. 
Dephosphorylation of activated IRS-1 and other, unknown substrates; 
association with activated growth factor receptors, where it may also provide 
an adapter fu~ re.ion within sig~alling complexes; postulated role in normal 
insulin signalling and growth control; no known human genetic diseases 
caused by its mutation have been identified. 
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host cell ~ integrins. The cytoplasmic domains of 
these receptors are in contact with the cytoskeleton 
at focal adhesions 9. It is thought that PTK ac- 
tivity induced by integdns upon llgand (invasin) 
binding triggers cytoskeletal reorganization, result- 
ing in phagocytosis of the bacterium by epithelial 
cells 8. 
Yersiniae neutralize phagocytes such as macro- 
phages by attaching to them and then, by a mech- 
anism that is not understood, secreting virulence 
determinants, called Yops, into these cells ~°. Yops 
are encoded by a 70 kb virulence plasmid. Of the 
ten or eleven Yop proteins, one, YopH (also known 
as Yop2b and YopS1) is a PTP. YopH is essential 
for virulence: deletion of the gene in Y. pseudo- 
tuberculosis impairs the ability of the bacteria to 
resist phagocytosis~L The YopH PTP is the most 
active PTP yet isolated ~. The importance of this ac- 
tivity to bacterial virulence is underscored by the fact 
that mutation of the actiw.site cysteine to alanine 
renders the PTP inactive and the bacterium 
avirulent n. 
The targets of YopH are unknown, but may include 
tyrosine-phosphorylated proteins involved in the 
YopH I I 
VH1 I I 
MKP [ ] 
1__  HCP ~ j 
$H-PTP2 ~ ~ 
Syp 
FIGURE 1 
Domain structure of PTPs. The core PTP domain is shown as 
a shaded rectangle. Some PTPs have unique N- or C-terminal 
extensions. SH2 domains - 100 amino acid modules that 
recognize phosphotyrosine (in the same protein or other 
protein) in the context of surrounding sequences 48 - are 
shown as small squares. The SH2 domain may serve to 
localize a PTP to a specific compartment within the cell or 
may also function to regulate activity, csw and SH-PTP2/Syp 
have the same SH2-SH2-PTP structure as HCP but they are 
more closely related to each other than to HCP and are 
considered homologues 4o, In addition, csw, but not 
SH-PTP2/Syp, has a 150 amino acid serine- and cysteine-rich 
insert (ins) of unknown function In its PTP domain 41, 
cytoskeletal reorganization that leads to phago- 
cytosis, as well as phosphoproteins important in 
signal t~ansduction. Yersinia infection of cultured 
macrophages results in reduction of the level of 
phosphotyrosine on many cellular proteins ~z. Two 
putative YopH substrates, a 120 kDa and a 55 kDa 
phosphoprotein, have been identified 12,~3. The phos- 
photyrosine levels of the 120 kDa protein decrease 
during the course of Yersinia infection of a macro- 
phage cell line 13. This effect is dependent on a func- 
tional YopH protein, since the phosphorylation level 
of this protein is constant in the presence of a 
catalytically inactive YopH mutant (in which the 
active-site cysteine has been replaced by alanine). 
The catalytically inactive nmtant protein was used to 
coimmunoprecipitate both the 120 kDa and 55 kDa 
proteins. These proteins each autophosphorylate 
on tyrosine in vitro. Their identities remain to be 
determined. 
The vacclnla vires FI'P: Impact  on the  cell cycle? 
The viral genus Orthopoxvirus includes members 
that cause smallpox. These viruses, now eliminated 
as source of disease, enter the host through the upper 
respiratory tract, are drained by the lymphatics to the 
lymph nodes and enter the bloodstream t4. They 
invade the reticuloendothelial system and then the 
epidermis, causing skin eruptions. Further conse- 
quences of viral infection include general toxemia, 
septic shock, intravascular coagulation, and death. 
One relatively benign member of this viral genus, 
vaccinia, has been studied extensively. Vacclnla virus 
is a large (192 000 bp) double-stranded DNA virus, 
containing ~200 genes, that replicates in the cyto- 
plasm of the host cell Is. In addition to encoding an 
impressive array of enzymes concerned with viral 
DNA replication and transcription, the virus encodes 
many proteins that inhibit host cell DNA, RNA and 
protein synthesis and defend the virus against the 
host immune system. 
Vacclnla virus encodes a small (20 kDa) PTP of 
unknown function called VHI (for vacclnla Hlndlll 
fragment H, ORF I) that is produced late in infec- 
tion I~. This FI'P is unusual in that it contains only 
the actlve.site signature sequence, with no readily 
identifiable regulatory sequences 16:7 (Fig, I). The 
VHI gene is highly conserved among the ortho- 
poxvlruses ~a and this fact, along with the compact 
nature of the viral genome, makes it likely that VHI 
plays an important role in the viral llfe cycle. The 
protein substrate(s) of VHI are unknown. 
VHI is the prototype of a family of PTPs that can 
dephosphorylate both phosphotyroslne- and phos- 
phoserlne/th~eonlne-contalnlng substrates ~7. Other 
dual-specific phosphatases have been discovered 
recently and many of them are involved, directly or 
indirectly, in regulation of the cell cycle. The active- 
site region of VH1 is similar to that of the mitotic regu- 
lator cdc2S, which dephosphorylates the cdc2 kinase 
on Thrl4 and TyrlS to allow entry into mitosis t9.2°. 
PTPs that are induced in response to mitogen stimu- 
lation (PACI, MKP-1), oxidative stress and heat shock 
(CLI00) in mammalian cells, and mating factor 
(MSGS) and nitrogen starvation (YVH1) in yeast 21-2s, 
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also appear to be dual-specific. PAC-1, MPK-1, CLIO0 
and MSGS dephosphorylate mitogen-activated pro- 
tein (MAP) kinases 24,26-2s. MAP l-dnases are a family 
of serine/threonine kinases activated by phos- 
phorylation on conserved threonine and tyrosine 
residues in response to a variety of growth factors 
and hormones 29,3°. They are key players in signal 
transduction cascades that link receptor protein tyro- 
sine ldnases to nuclear transcription factors in 
mammalian cells and to the transcriptional and cell 
cycle machinery in yeast. Depending on the stimu- 
lus, cells may undergo either cell cycle progression 
or arrest. The dual-specific phosphatases may regu- 
late these pathways by preventing either excess- 
ive growth or prolonged quiescence. It is tempting 
to speculate that VH1 interferes with the cell 
cycle by competing with an endogenous dual- 
specific phosphatase for its substrate. Further inves- 
tigation is needed in order to identify changes 
effected at both the cellular and molecular levels 
by VH1. 
Endogenous PTPs In cell growth and 
developmental regu la t ion 
Although no human diseases have been clearly 
ascribed to defective PTP function, studies of the 
mouse haematopoietic cell phosphatase (HCP) and 
Drosophila corkscrew (csw) have shown that aberrant 
patterns of growth and development may occur 
when normal copies of cellular PTPs are mutated 31. 
In addition, as discussed below, mammalian homol- 
ogues of csw are found to be associated with activated 
growth factor receptors 32"34, as well as insulin recep- 
tor substrate-1 (IRS-1)3s; the study of these inter- 
actions may shed light on diseases as diverse as 
cancer and diabetes. 
HCP and the csw family of PTPs are cytoplasmic 
proteins that have a common structure, consisting of 
two N-terminal SH2 domains, a single central VI'P 
domain, and a C-terminal tail (Fig. 1), tlCP (also 
known as SH-FI'PI and PTPlC) is a 68 kDa protein 
produced in a variety of mouse and human primary 
haematopoletic cells and cell lines a6. Mice homo- 
zygous for the recessive motheaten (me) allele, or the 
less severe me" allele, carry mutations in the gene 
encoding HCP and have a variety of immune cell 
deficiencies ~7. These include defects in lymphocyte, 
natural killer cell, and macrophage development 
and/or function, leading to death after several weeks 
to a few months. The me and me ~ mutations are 
single base-pair changes that cause aberrant splicing 
of the HCP mRNA 37-39 and synthesis of an out.of- 
frame, truncated PTP in me/me mice, or lead to 
proteins with small deletions or insertions of amino 
acids in me'Tree ~ mice. In both cases, HCP enzyme 
activity in macrophages is reduced. The human HCP 
gene maps to chromosome 12p12-p13, a region that 
is associated w',tb rearrangements in 10% of cases of 
childhood acute lymphocytic leukaemia. Other dis- 
eases that might originate from defects in HCP are 
several types of familial immunological dysfunc- 
tions, whose clinical manifestations are similar to 
those displayed by me~me or meVme" mice (reviewed 
in Ref. 37). 
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In contrast to HCP, which is produced primarily 
in cells of haematopoietic lineage, the Drosophila 
corkscrew (csw) protein and its human (SH-PTP2) 
and mouse (Syp) homologues appear to be produced 
ubiquitously in different tissues and throughout 
development34.4°o4L However, csw has a specific role 
in Drosophila development: csw mutants form invi- 
able zygotes with abnormal development of their 
terminal (head and tail) stmctures4L 
Several lines of evidence suggest that csw and its 
mammalian relatives interact with activated growth 
factor receptors: genetic epistasis experiments indi- 
cate that during development csw acts downstream 
of the torso receptor (a homologue of the PDGF 
receptor), and in concert with the Drosophila Raf pro- 
tein, to transduce signals to downstream transcription 
factors41; SH-PTP2/Syp coimmunoptecipitates the 
EGF and PDGF receptors, with association increasing 
after growth factor stimulation33.34; and a phospho- 
tyrosyl peptide of the PDGF receptor (comprising the 
SH-PTP2/Syp-binding site as defined by peptide com- 
petition experiments) was found to stimulate the 
activity of SH.PTP2/Syp five- to tenfold 42. 
It is not clear whether the growth factor receptors 
are substrates for these IrfPs since the EGF receptor 
was not dephosphorylated by SH-PTP2/Syp under 
conditions where SH-PTP2/Syp was active in dephos- 
phorylation of an artificial substrate 34. Rather, bind- 
ing of these PTPs to activated growth factor receptors 
via SH2 domains may be a prerequisite for down- 
stream signal transduction events. Before growth 
factor stimulation, SH-PTP2/Syp is phosphorylated 
predominantly on threonine and serine; after stimu- 
lation, phosphorylation is found on tyrosine 33. These 
results suggest a model in which the PTP associates 
with an activated, tyroslne-phosphorylated growth 
factor receptor via SH2 domains, is phosphorylated 
on tyrosine, and then itself becomes a potential 
target for binding of other SH2.domain proteins, 
possibly substrates. Evidence in support of this model 
is that PDGF sthnulation induces the formation of 
a complex containing the PDGF receptor, Sos (a 
guanine.nucleotide-exchange factor that activates 
Ras), Grb2 (an adapter protein that links Sos and Ras), 
and SH-PTP2/Syp 4~. In this complex, SH.PTP2/Syp 
joins Grb2 to the PDGF receptor. Thus at least one of 
the signalling funct'lons of SH-PTP2/Syp may be as an 
adapter, coupling FDGF receptor activity to Ras acti. 
ra t ion of the ldnase cascade that in turn leads to 
cellular proliferation. 
In addition to an involvement in growth factor sig- 
nalling, SI-I.PTP2/Syp is involved in insulin sig- 
nalling. Insulin binding causes the insulin receptor 
to autophosphorylate on tyrosine, and then the acti- 
vated receptor phosphorylates substrate proteins on 
tyrosine 44. One of these, IRS- 1, binds SH2<lomain pro- 
teins that dock at multiple tyrosine-phosphorylated 
sites. In adipocytes treated with insulin, SH-PTP2/Syp 
was found to be associated with IRS.13s. Association 
between SH.PTP2/Syp and IRS.1 leads to the rapid 
dephosphorylation of IRS-14s. Specific phosphotyro- 
syl peptides from IRS-1 stimulated the PTP activity of 
SH-PTP2/Syp towards artificial substrates up to SO- 
fold 46. Surface plasmon resonance studies reveaicd 
429 
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that other phosphotyrosyl peptides from IRS-1 bound  
strongly to either the N-terminal or C-terminal SH2 
domain from SH-FrP2/Syp 46. These data suggest that 
each SH2 domain can bind to a disUnct phospho- 
tymsine residue of IRS-1 while activating hydrolysis 
of a third phosphotyrosine residue at the active site. 
Why is SI-_'-PTP2/Syp associated with IRS-1 and 
what is its role in insulin signalling? When tyrosine 
phosphorylation of the insulin receptor is stopped 
by permeabtlizaUon of adipocytes in the pres- 
ence of EDTA, IRS-1 is rapidly dephosphorylated 47. 
Dephosphorylation of IRS-1 might be part of the 
mechanism responsible for the cessation of signalling 
in response to insulin withdrawal. Alternatively, SH- 
Fl'P2/Syp might act in an analogous way to csw, 
which transduces the signal emanating from the 
torso receptor in a positive manner. If this is the case, 
dephosphorylation of IRS-1 or other substrates might 
be necessary for propagation of the insulin-induced 
signal. 
Future directions 
The studies described in this article represent a start 
towards understanding the role of PTPs in disease 
processes. At the same time, they are providing 
insight into the basic biology of the regulatory net- 
works that are affected by PTPs. In order to under- 
stand what roles PTPs are playing, two major ques- 
tions remain to be answered: what are the substrates 
for these phosphatases, and do the phosphatases 
function as early players in signal transductlon 
pathways or do they function later in adaptation 
or response cessation? Answering these questions 
wi l l  increase our  unders tand ing  of  norma l  g rowth  
and deve lopment  as we l l  as the molecular  basis 
o f  disease, 
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